Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.

  title={Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.},
  author={Julio Rosenstock and David R Hassman and Robert D Madder and Shari A Brazinsky and James D. Farrell and Naum M. Khutoryansky and Paula M. Hale},
  journal={Diabetes care},
  volume={27 6},
OBJECTIVE A randomized, parallel-group, open-label, multicenter 16-week clinical trial compared efficacy and safety of repaglinide monotherapy and nateglinide monotherapy in type 2 diabetic patients previously treated with diet and exercise. RESEARCH DESIGN AND METHODS Enrolled patients (n = 150) had received treatment with diet and exercise in the previous 3 months with HbA(1c) >7 and < or =12%. Patients were randomized to receive monotherapy with repaglinide (n = 76) (0.5 mg/meal, maximum… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 57 extracted citations


Publications referenced by this paper.
Showing 1-10 of 17 references

Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes

  • J Rosenstock, MR Gatlin, SG Shen, JE Foley
  • Diabetes Care 25:1529–1533,
  • 2002

Comparison between re paglinide and glipizide in type 2 diabetes mellitus: a 1-year multicentre study

  • S Madsbad, B Kilhovd, I Lagert, P Mustajoki, A Dejgaard
  • Diabet Med
  • 2001

IH: Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes

  • LF Van Gaal, KL Van Acker, Leeuw de
  • Diabetes Res Clin Pract 53:141–148,
  • 2001

Similar Papers

Loading similar papers…